ULTRAGENYX PHARMACEUTICAL INC. Debt Securities, Available-for-sale, Noncurrent
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Debt Securities, Available-for-sale, Noncurrent of $144.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $144.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $121.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $57.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $22.07M.
| Period end | Debt Securities, Available-for-sale, Noncurrent | Debt Securities, Available-for-sale, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $144.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $121.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $57.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $22.07M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $51.45M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $68.56M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $135.00M 10-K · filed 2026-02-18 | $135.00M 10-K · filed 2025-02-19 |
| 2024-09-30 | $203.09M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $110.67M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $156.58M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $199.90M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $82.07M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $66.37M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $85.21M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $148.97M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $107.56M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $163.30M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $215.53M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $258.93M 10-K · filed 2023-02-17 | |
| 2021-09-30 | $204.24M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $128.03M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $81.62M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $10.51M 10-K · filed 2022-02-15 | |
| 2019-12-31 | $5.17M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |